September 19, 2016 - Drug therapy with beta blockers represents the therapeutic mainstay for both LQTS and CPVT. Our goal is to help clinicians understand the importance of beta blocker therapy in these two genetic disorders, as well as to provide clinical guidance on the choice of agents. Nadolol, when available, has been the preferred beta blocker utilized by the largest LQTS/CPVT specialty centers throughout the world for the past 25 years.
Search for "" returned 92 matches
2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion1279
October 2006 — Developed in collaboration With the Heart Rhythm Society, this competence statement was designed to assist in the assessment of physicians' competence on a procedure-specific basis. The update specifies the minimum education, training, experience, and cognitive and technical skills necessary for the competent performance of invasive cardiac electrophysiology, catheter ablation, and cardioversion.
June 26, 2000 — These guidelines present an approach to the use of amiodarone in clinical practice.
Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies23850
May 5, 2011 (Updated August 1, 2011) – Genetic testing is increasingly important in determining potential cardiac conditions in patients and is used in clinical settings more than ever before. To ensure that physicians have up-to-date knowledge of the evolving role of genetic testing for sudden death predisposing, genetic heart diseases in cardiology, which can be life-saving for some patients, the Heart Rhythm Society and the European Heart Rhythm Association have prepared HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. The consensus statement was released at Heart Rhythm 2011, the Heart Rhythm Society’s 32nd Annual Scientific Sessions.
December 10, 2015 - The evolution of LAA occlusion technology has spanned nearly two decades and three FDA panel hearings, leading to FDA approval in 2015. As this technology becomes clinically available to a broader population of patients, it is essential that physician stakeholders establish criteria for the performance of these procedures that will be used in granting initial and ongoing privileges. These criteria are offered to support The Joint Commission mandate that medical staff privileges be granted on the basis of professional criteria specified in the medical staff bylaws to ensure safe and effective patient-centered care.
2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing24544
November 19, 2015 - The benefits and risks of ICD therapy for patients are directly impacted by the programming and surgical decisions made by the clinician. This expert consensus statement systemically describes four important clinical issues and addresses programming of: bradycardia mode and rate, tachycardia detection, tachycardia therapy, and intraprocedural testing of defibrillation efficacy.
February 1, 2015 - The Heart Rhythm Society convened a forum of stakeholders in medical device innovation in conjunction with the 2015 Heart Rhythm Society Annual Scientific Sessions. The forum facilitated open discussion on medical device innovation, including obstacles to physician involvement and possible solutions. This report is based on the themes that emerged.
2009 — The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association, the Heart Failure Association, and the Heart Rhythm Society. This is a revised version of the 2004 ESC Guidelines on Syncope.
August 15, 2006 — A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines
This document has been retired and replaced by "2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation."
2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death1340
September 5, 2006 — The guidelines, jointly created by the American College of Cardiology, American Heart Association and the European Society of Cardiology has been endorsed by the Heart Rhythm Society Board of Trustees, is giving you an update and combining the previously published recommendations regarding the management of patients with Ventricular arrhythmias into one source.